Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations Khoury HJ; Guilhot F; Hughes TP; Kim DW; Cortes JECancer 2009[Apr]; 115 (7): 1381-94Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia. Across a series of phase 2 and 3 trials, dasatinib was associated with durable treatment responses in all phases of the disease and was well tolerated. For this article, the authors reviewed available information on specific side effects associated with the use of dasatinib. On the basis of more than 2 years' experience of dasatinib treatment during clinical trials, they provide practical recommendations for side-effect management.|Clinical Trials as Topic[MESH]|Contraindications[MESH]|Dasatinib[MESH]|Drug Interactions[MESH]|Gastrointestinal Tract/drug effects[MESH]|Heart Diseases/chemically induced[MESH]|Hematologic Diseases/chemically induced[MESH]|Humans[MESH]|Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy[MESH]|Pleural Effusion/chemically induced[MESH]|Pyrimidines/*adverse effects[MESH]|Thiazoles/*adverse effects[MESH] |
